Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update DALLAS, TX, March 21, 2024 (GLOBE NEWSWIRE) Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: • Announced a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TI ...